PARP-1 inhibitors: A novel genetically specific agents for cancer therapy

Neoplasma

Volumn 57, Issue 5, 2010, Pages 401-405

  Cipak, L ^a   Jantova, S ^b  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

Author keywords

BRCA1; BRCA2; DNA repair; PARP 1 inhibitor; Synthetic lethality

Indexed keywords

3 AMINOBENZAMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; BENZIMIDAZOLE DERIVATIVE; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEP 9722; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; INIPARIB; INO 1001; IRINOTECAN; MITOMYCIN C; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PACLITAXEL; PEMETREXED; RUCAPARIB; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VELIPARIB; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, HUMAN;

ADVANCED CANCER; BREAST CANCER; CANCER MORTALITY; CANCER THERAPY; CARCINOSARCOMA; CELL CYCLE; CELL DEATH; CELL SURVIVAL; CHEMOSENSITIZATION; CHROMOSOMAL INSTABILITY; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; GENE MUTATION; GLIOMA; HOMOLOGOUS RECOMBINATION; HUMAN; IC 50; IN VITRO STUDY; LEUKEMIA; MELANOMA; MYELODYSPLASTIC SYNDROME; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; REVIEW; SOLID TUMOR; UTERUS TUMOR; ANIMAL; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; NEOPLASM;

ANIMALS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 79952109500     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_05_401     Document Type: Review

References (39)

1. HOEIJMAKERS JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001; 411: 366-74. doi:10.1038/ 35077232
2. KAELIN WG JR. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005; 5: 689-98. doi:10.1038/nrc1691
3. GARBER JE, OFFIT K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005; 23: 276-92. doi:10.1200/ JCO.2005.10.042
4. ECCLES DM, PICHERT G. Familial non-BRCA1/BRCA2-associated breast cancer. Lancet Oncol. 2005; 6: 705-11. doi:10.1016/S1470-2045(05)70318-1
5. FARMER H, MCCABE N, LORD CJ, TUTT AN, JOHNSON DA et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434: 917-21. doi:10.1038/nature03445
6. CHAMBON P, WEILL JD, MANDEL P. Nicotinamide mononucleotide activation of new DNA dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun. 1963; 11: 39-43. doi:10.1016/0006-291X(63)90024-X
7. VENKITARAMAN AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002; 108: 171-82. doi:10.1016/S0092-8674(02)00615-3
8. GREENBERG RA. Recognition of DNA double strand breaks by the BRCA1 tumor supressor network. Chromosoma. 2008; 117: 305-17. doi:10.1007/s00412-008-0154-8
9. YANG H, JEFFREY PD, MILLER J, KINNUCAN E, SUN Y et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science. 2002; 297: 1837-48. doi:10.1126/science.297.5588.1837
10. BURKLE A. Poly(ADP-ribose). The most elaborate metabolite of NAD+. FEBS J. 2005; 272: 4576-89. doi:10.1111/j.1742-4658.2005.04864.x
11. HASSA PO, HOTTIGER MO. The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008; 13: 3046-82. doi:10.2741/2909
12. SCHREIBER V, HUNTING D, TRUCCO C, GOWANS B, GRUNWALD D et al. A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage. Proc Natl Acad Sci USA. 1995; 92: 4753-7. doi:10.1073/ pnas.92.11.4753
13. HASSA PO. The molecular "Jekyll and Hyde" duality of PARP1 in cell death and cell survival. Front Biosci. 2009; 14: 72-111.
14. PALOMBA L, SESTILI P, COLUMBARO M, FALCIERI E, CANTONI O. Apoptosis and necrosis following exposure of U937 cells to increasing concentrations of hydrogen peroxide: the effect of the poly(ADP-ribose)polymerase inhibitor 3-aminobenzamide. Biochem Pharmacol. 1999; 58: 1743-50. doi:10.1016/S0006-2952(99)00271-3
15. KEHE K, RAITHEL K, KREPPEL H, JOCHUM M, WOREK F et al. Inhibition of poly(ADP-ribose) polymerase (PARP) influences the mode of sulfur mustard (SM)-induced cell death in HaCaT cells. Arch Toxicol. 2008; 82: 461-70. doi:10.1007/ s00204-007-0265-7
16. MCCABE N, LORD CJ, TUTT AN, MARTIN NM, SMITH GC et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly(ADP-ribose) polymerase: an issue of potency. Cancer Biol Ther. 2005; 4: 934-6
17. BRYANT HE, SCHULTZ N, THOMAS HD, PARKER KM, FLOWER D et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434: 913-7 doi:10.1038/nature03443
18. ROTTENBERG S, JASPERS JE, KERSBERGEN A, VAN DER BURG E, NYGREN AO et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008; 105: 17079-84. doi:10.1073/pnas.0806092105
19. MCLICK J, HAKAM A, BAUER PI, KUN E, ZACHARIAS DE et al. Benzamide-DNA interactions: deductions from binding, enzyme kinetics and from X-ray structural analysis of a 9-ethyladenine-benzamide adduct. Biochim Biophys Acta. 1987; 909: 71-83.
20. SOUTHAN GJ, SZABO C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem. 2003; 10: 321-40.
21. MILAM KM, CLEAVER JE. Inhibitors of poly(adenosine diphosphate-ribose) synthesis: effectonothermetabolicprocesses. Science. 1984; 223: 589-91. doi:10.1126/science.6420886
22. SUTO MJ, TURNER WR, ARUNDEL SUTO CM, WERBEL LW, SEBOLT-LEOPOLD JS. Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des. 1991; 6: 107-17.
23. BRANCA D, CERRETANI M, JONES P, KOCH U, ORVIETO F et al. Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2009; 19: 4042-5. doi:10.1016/ j.bmcl.2009.06.031
24. CANAN KOCH SS, THORESEN LH, TIKHE JG, MAEGLEY KA, ALMASSY RJ et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem. 2002; 45: 4961-74. doi:10.1021/jm020259n
25. CALABRESE CR, BATEY MA, THOMAS HD, DURKACZ BW, WANG LZ et al. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003; 9: 2711-8.
26. WHITE AW, ALMASSY R, CALVERT AH, CURTIN NJ, GRIFFIN RJ et al. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J Med Chem. 2000; 43: 4084-97. doi:10.1021/jm000950v
27. DELANEY CA, WANG LZ, KYLE S, WHITE AW, CALVERT AH et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res. 2000; 6: 2860-7.
28. BANASIK M, KOMURA H, SHIMOYAMA M, UEDA K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADPribosyl) transferase. J Biol Chem. 1992; 267: 1569-75.
29. LOH VMJR, COCKCROFT XL, DILLAN KJ, DIXON L, DRZEWIECKI J et al. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADPribose) polymerase. Bioorg Med Chem Lett. 2005; 15: 2235-8. doi:10.1016/j.bmcl.2005.03.026
30. WHITE AW, CURTIN NJ, EASTMAN BW, GOLDING BT, HOSTOMSKY Z et al. Potentiation of cytotoxic drug activity in human tumour cell lines, by aminesubstituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg Med Chem Lett. 2004; 14: 2433-7. doi:10.1016/j.bmcl.2004.03.017
31. GRIFFIN RJ, SRINIVASAN S, BOWMAN K, CALVERT AH, CURTIN NJ et al. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J Med Chem. 1998; 41: 5247-56. doi:10.1021/jm980273t
32. JAGTAP PG, BALOGLU E, SOUTHAN GJ, MABLEY JG, LI H et al. Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005; 48: 5100-3. doi:10.1021/jm0502891
33. ABDELKARIM GE, GERTZ K, HARMS C, KATCHANOV J, DIRNAGL U et al. Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med. 2001; 7: 255-60.
34. MCCABE N, TURNER NC, LORD CJ, KLUZEK K, BIALKOWSKA A et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADPribose) polymerase inhibition. Cancer Res. 2006; 66: 8109-15. doi:10.1158/0008-5472.CAN-06-0140
35. MENDES-PEREIRA AM, MARTIN SA, BROUGH R, MCCARTHY A, TAYLOR JR et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med. 2009; 1: 315-22.
36. http://clinicaltrials.gov/
37. EDWARDS SL, BROUGH R, LORD CJ, NATRAJAN R, VATCHEVA R et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008; 451: 1111-5. doi:10.1038/ nature06548
38. SAKAI W, SWISHER EM, KARLAN BY, AGARWAL MK, HIGGINS J et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature, 2008; 451: 1116-20. doi:10.1038/nature06633
39. TURNER N, LORD C, IORNS E, BROUGH R, SWIFT S et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008; 27: 1368-77. doi:10.1038/emboj.2008.61